Oral cyclodextrin supramolecular for ulcerative colitis treatment through macrophages targeting / ROS response-based accurate on-demand drug release strategy
Cyclodextrins (CDs) have been applied widely as an oral micro-nano drug delivery material for the treatment of ulcerative colitis (UC) because of their stability around the stomach. However, the further application of CDs is hindered due to their inherent poor targeting and controlled release proper...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-02-01
|
| Series: | Materials & Design |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0264127523000217 |
| _version_ | 1811158416442261504 |
|---|---|
| author | Haiting Xu Linxin Dai Wenbiao Nie Ruifeng Luo Xiulan Pu Lingling Dong Qiyan Chen Shanshan Qi Xiaoqin Han Jieshu You Jinming Zhang Fei Gao |
| author_facet | Haiting Xu Linxin Dai Wenbiao Nie Ruifeng Luo Xiulan Pu Lingling Dong Qiyan Chen Shanshan Qi Xiaoqin Han Jieshu You Jinming Zhang Fei Gao |
| author_sort | Haiting Xu |
| collection | DOAJ |
| description | Cyclodextrins (CDs) have been applied widely as an oral micro-nano drug delivery material for the treatment of ulcerative colitis (UC) because of their stability around the stomach. However, the further application of CDs is hindered due to their inherent poor targeting and controlled release properties. In this study, CD-supramolecular nanoparticles (HA-CsT@RH) were developed based on the structural characteristics of CDs (e.g., multi-group modifiability and hydrophobic cavity) to encapsulate rhein (RH) for oral delivery against UC. The HA-CsT@RH showed an average size of 154.70 ± 1.80 nm and exhibited high encapsulation efficiency (95.55 ± 2.37 %). When incubated in simulated gastric fluid for 2 h, HA-CsT@RH only released 20.3 ± 0.47 % RH due to the protection of supramolecular effects of CDs. However, RH was rapidly released from HA-CsT@RH (released 66.3 ± 2.50 %) after H2O2 was treated with the assistance of the ROS-sensitive properties. Moreover, HA-CsT@RH were taken up by macrophages in 1.5 times higher amounts than preparations which did not have CD44-targeted effects. Notably, the results showed that HA-CsT@RH with an accurate on-demand drug release strategy achieved the best anti-inflammatory and antioxidant effects, and they are expected to be a promising carrier in the UC treatment. |
| first_indexed | 2024-04-10T05:24:18Z |
| format | Article |
| id | doaj.art-03a78e2c8cf147d3bdef4f7c2be413d4 |
| institution | Directory Open Access Journal |
| issn | 0264-1275 |
| language | English |
| last_indexed | 2024-04-10T05:24:18Z |
| publishDate | 2023-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Materials & Design |
| spelling | doaj.art-03a78e2c8cf147d3bdef4f7c2be413d42023-03-08T04:13:28ZengElsevierMaterials & Design0264-12752023-02-01226111606Oral cyclodextrin supramolecular for ulcerative colitis treatment through macrophages targeting / ROS response-based accurate on-demand drug release strategyHaiting Xu0Linxin Dai1Wenbiao Nie2Ruifeng Luo3Xiulan Pu4Lingling Dong5Qiyan Chen6Shanshan Qi7Xiaoqin Han8Jieshu You9Jinming Zhang10Fei Gao11State Key Laboratory of Southwestern Chinese Medicine Resources, Pharmacy School, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, ChinaState Key Laboratory of Southwestern Chinese Medicine Resources, Pharmacy School, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, ChinaState Key Laboratory of Southwestern Chinese Medicine Resources, Pharmacy School, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, ChinaState Key Laboratory of Southwestern Chinese Medicine Resources, Pharmacy School, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, ChinaState Key Laboratory of Southwestern Chinese Medicine Resources, Pharmacy School, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, ChinaState Key Laboratory of Southwestern Chinese Medicine Resources, Pharmacy School, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, ChinaState Key Laboratory of Southwestern Chinese Medicine Resources, Pharmacy School, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, ChinaState Key Laboratory of Southwestern Chinese Medicine Resources, Pharmacy School, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, ChinaState Key Laboratory of Southwestern Chinese Medicine Resources, Pharmacy School, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, ChinaCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China; Corresponding authors.State Key Laboratory of Southwestern Chinese Medicine Resources, Pharmacy School, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, China; Corresponding authors.State Key Laboratory of Southwestern Chinese Medicine Resources, Pharmacy School, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, China; Corresponding authors.Cyclodextrins (CDs) have been applied widely as an oral micro-nano drug delivery material for the treatment of ulcerative colitis (UC) because of their stability around the stomach. However, the further application of CDs is hindered due to their inherent poor targeting and controlled release properties. In this study, CD-supramolecular nanoparticles (HA-CsT@RH) were developed based on the structural characteristics of CDs (e.g., multi-group modifiability and hydrophobic cavity) to encapsulate rhein (RH) for oral delivery against UC. The HA-CsT@RH showed an average size of 154.70 ± 1.80 nm and exhibited high encapsulation efficiency (95.55 ± 2.37 %). When incubated in simulated gastric fluid for 2 h, HA-CsT@RH only released 20.3 ± 0.47 % RH due to the protection of supramolecular effects of CDs. However, RH was rapidly released from HA-CsT@RH (released 66.3 ± 2.50 %) after H2O2 was treated with the assistance of the ROS-sensitive properties. Moreover, HA-CsT@RH were taken up by macrophages in 1.5 times higher amounts than preparations which did not have CD44-targeted effects. Notably, the results showed that HA-CsT@RH with an accurate on-demand drug release strategy achieved the best anti-inflammatory and antioxidant effects, and they are expected to be a promising carrier in the UC treatment.http://www.sciencedirect.com/science/article/pii/S0264127523000217Cyclodextrin supramolecular nanoparticlesRheinMacrophage targetingROS-responsiveUlcerative colitis |
| spellingShingle | Haiting Xu Linxin Dai Wenbiao Nie Ruifeng Luo Xiulan Pu Lingling Dong Qiyan Chen Shanshan Qi Xiaoqin Han Jieshu You Jinming Zhang Fei Gao Oral cyclodextrin supramolecular for ulcerative colitis treatment through macrophages targeting / ROS response-based accurate on-demand drug release strategy Materials & Design Cyclodextrin supramolecular nanoparticles Rhein Macrophage targeting ROS-responsive Ulcerative colitis |
| title | Oral cyclodextrin supramolecular for ulcerative colitis treatment through macrophages targeting / ROS response-based accurate on-demand drug release strategy |
| title_full | Oral cyclodextrin supramolecular for ulcerative colitis treatment through macrophages targeting / ROS response-based accurate on-demand drug release strategy |
| title_fullStr | Oral cyclodextrin supramolecular for ulcerative colitis treatment through macrophages targeting / ROS response-based accurate on-demand drug release strategy |
| title_full_unstemmed | Oral cyclodextrin supramolecular for ulcerative colitis treatment through macrophages targeting / ROS response-based accurate on-demand drug release strategy |
| title_short | Oral cyclodextrin supramolecular for ulcerative colitis treatment through macrophages targeting / ROS response-based accurate on-demand drug release strategy |
| title_sort | oral cyclodextrin supramolecular for ulcerative colitis treatment through macrophages targeting ros response based accurate on demand drug release strategy |
| topic | Cyclodextrin supramolecular nanoparticles Rhein Macrophage targeting ROS-responsive Ulcerative colitis |
| url | http://www.sciencedirect.com/science/article/pii/S0264127523000217 |
| work_keys_str_mv | AT haitingxu oralcyclodextrinsupramolecularforulcerativecolitistreatmentthroughmacrophagestargetingrosresponsebasedaccurateondemanddrugreleasestrategy AT linxindai oralcyclodextrinsupramolecularforulcerativecolitistreatmentthroughmacrophagestargetingrosresponsebasedaccurateondemanddrugreleasestrategy AT wenbiaonie oralcyclodextrinsupramolecularforulcerativecolitistreatmentthroughmacrophagestargetingrosresponsebasedaccurateondemanddrugreleasestrategy AT ruifengluo oralcyclodextrinsupramolecularforulcerativecolitistreatmentthroughmacrophagestargetingrosresponsebasedaccurateondemanddrugreleasestrategy AT xiulanpu oralcyclodextrinsupramolecularforulcerativecolitistreatmentthroughmacrophagestargetingrosresponsebasedaccurateondemanddrugreleasestrategy AT linglingdong oralcyclodextrinsupramolecularforulcerativecolitistreatmentthroughmacrophagestargetingrosresponsebasedaccurateondemanddrugreleasestrategy AT qiyanchen oralcyclodextrinsupramolecularforulcerativecolitistreatmentthroughmacrophagestargetingrosresponsebasedaccurateondemanddrugreleasestrategy AT shanshanqi oralcyclodextrinsupramolecularforulcerativecolitistreatmentthroughmacrophagestargetingrosresponsebasedaccurateondemanddrugreleasestrategy AT xiaoqinhan oralcyclodextrinsupramolecularforulcerativecolitistreatmentthroughmacrophagestargetingrosresponsebasedaccurateondemanddrugreleasestrategy AT jieshuyou oralcyclodextrinsupramolecularforulcerativecolitistreatmentthroughmacrophagestargetingrosresponsebasedaccurateondemanddrugreleasestrategy AT jinmingzhang oralcyclodextrinsupramolecularforulcerativecolitistreatmentthroughmacrophagestargetingrosresponsebasedaccurateondemanddrugreleasestrategy AT feigao oralcyclodextrinsupramolecularforulcerativecolitistreatmentthroughmacrophagestargetingrosresponsebasedaccurateondemanddrugreleasestrategy |